AR004940A1 - Procedimiento para controlar la cantidad de acido sialico presente sobre una cadena lateral de oligosacaridos de una glicoproteina producida por cultivo en una celula hospedante de mamifero. - Google Patents

Procedimiento para controlar la cantidad de acido sialico presente sobre una cadena lateral de oligosacaridos de una glicoproteina producida por cultivo en una celula hospedante de mamifero.

Info

Publication number
AR004940A1
AR004940A1 ARP960103001A AR10300196A AR004940A1 AR 004940 A1 AR004940 A1 AR 004940A1 AR P960103001 A ARP960103001 A AR P960103001A AR 10300196 A AR10300196 A AR 10300196A AR 004940 A1 AR004940 A1 AR 004940A1
Authority
AR
Argentina
Prior art keywords
sialic acid
cell culture
cell
culture
hospedant
Prior art date
Application number
ARP960103001A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23863440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR004940(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of AR004940A1 publication Critical patent/AR004940A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP960103001A 1995-06-06 1996-06-06 Procedimiento para controlar la cantidad de acido sialico presente sobre una cadena lateral de oligosacaridos de una glicoproteina producida por cultivo en una celula hospedante de mamifero. AR004940A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/469,348 US5705364A (en) 1995-06-06 1995-06-06 Mammalian cell culture process

Publications (1)

Publication Number Publication Date
AR004940A1 true AR004940A1 (es) 1999-04-07

Family

ID=23863440

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960103001A AR004940A1 (es) 1995-06-06 1996-06-06 Procedimiento para controlar la cantidad de acido sialico presente sobre una cadena lateral de oligosacaridos de una glicoproteina producida por cultivo en una celula hospedante de mamifero.
ARP980100640A AR011439A2 (es) 1995-06-06 1998-02-12 Procedimiento para producir quimeras de inmunoglobulina (ig) del receptor del factor de necrosis tumoral (tnfr), nuevas preparaciones igg1 del tnfr1 yuna composicion terapeutica que los contiene

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP980100640A AR011439A2 (es) 1995-06-06 1998-02-12 Procedimiento para producir quimeras de inmunoglobulina (ig) del receptor del factor de necrosis tumoral (tnfr), nuevas preparaciones igg1 del tnfr1 yuna composicion terapeutica que los contiene

Country Status (35)

Country Link
US (1) US5705364A (cg-RX-API-DMAC7.html)
EP (2) EP0832189B2 (cg-RX-API-DMAC7.html)
JP (2) JPH11507523A (cg-RX-API-DMAC7.html)
KR (1) KR100496356B1 (cg-RX-API-DMAC7.html)
CN (1) CN1166772C (cg-RX-API-DMAC7.html)
AR (2) AR004940A1 (cg-RX-API-DMAC7.html)
AT (2) ATE302266T1 (cg-RX-API-DMAC7.html)
AU (1) AU717847B2 (cg-RX-API-DMAC7.html)
BG (1) BG63213B1 (cg-RX-API-DMAC7.html)
BR (1) BR9609150A (cg-RX-API-DMAC7.html)
CA (1) CA2220684C (cg-RX-API-DMAC7.html)
CZ (1) CZ293719B6 (cg-RX-API-DMAC7.html)
DE (2) DE69637867D1 (cg-RX-API-DMAC7.html)
DK (2) DK0832189T4 (cg-RX-API-DMAC7.html)
EA (1) EA001215B1 (cg-RX-API-DMAC7.html)
ES (2) ES2248812T5 (cg-RX-API-DMAC7.html)
GE (1) GEP20012519B (cg-RX-API-DMAC7.html)
HU (1) HU226420B1 (cg-RX-API-DMAC7.html)
IL (1) IL122398A (cg-RX-API-DMAC7.html)
IS (1) IS2614B (cg-RX-API-DMAC7.html)
MY (1) MY113496A (cg-RX-API-DMAC7.html)
NO (1) NO322276B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ310202A (cg-RX-API-DMAC7.html)
OA (1) OA10753A (cg-RX-API-DMAC7.html)
PL (1) PL185484B1 (cg-RX-API-DMAC7.html)
PT (1) PT1609853E (cg-RX-API-DMAC7.html)
RO (1) RO120267B1 (cg-RX-API-DMAC7.html)
SA (1) SA96170351B1 (cg-RX-API-DMAC7.html)
SI (2) SI0832189T2 (cg-RX-API-DMAC7.html)
SK (1) SK282658B6 (cg-RX-API-DMAC7.html)
TR (1) TR199701543T1 (cg-RX-API-DMAC7.html)
TW (2) TW426734B (cg-RX-API-DMAC7.html)
UA (1) UA47428C2 (cg-RX-API-DMAC7.html)
WO (1) WO1996039488A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA964776B (cg-RX-API-DMAC7.html)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
KR20000010825A (ko) * 1996-05-08 2000-02-25 프리돌린 클라우스너, 롤란드 비. 보레르 종양괴사인자 수용체-면역 글로불린 융합 단백질을 사용한 천식의 치료방법
AU2051899A (en) * 1997-12-03 1999-06-16 Roche Diagnostics Gmbh Method for preparing polypeptides with appropriate glycosilation
US6140445A (en) * 1998-04-17 2000-10-31 Crompton Corporation Silane functional oligomer
AU4314299A (en) * 1998-05-29 1999-12-13 Genentech Inc. Cell culture process for producing glycoproteins
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
GB9828624D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Production of proteins
KR100475417B1 (ko) * 1998-12-30 2005-07-18 씨제이 주식회사 시알산 함량이 높은 재조합 당단백질의 제조방법
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
KR100394474B1 (ko) * 1999-12-18 2003-08-09 동아제약 주식회사 동물세포에서 재조합 당단백질의 연속식 대량생산 방법
ES2256234T3 (es) * 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
AU2001271021A1 (en) * 2000-07-05 2002-01-14 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
EP1404813A4 (en) * 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
EP1497444B1 (en) 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production
US20030190710A1 (en) * 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
CN100402660C (zh) * 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
MXPA05011486A (es) * 2003-04-25 2006-04-18 Immunex Corp Inductores de expresion de proteina recombinante.
SG147468A1 (en) 2003-10-24 2008-11-28 Selexis Sa High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
US20070099266A1 (en) * 2003-12-23 2007-05-03 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
EP1709185A1 (en) * 2003-12-31 2006-10-11 Samyang Genex Corporation Method for mass production of secondary metabolites in plant cell culture by treatment of an alkanoic acid or salt thereof
CN1926242B (zh) * 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP2008541746A (ja) * 2005-06-03 2008-11-27 ビオヴィトルム・アクチボラゲット（プブリクト） 新規プロセス
KR100670105B1 (ko) 2005-06-29 2007-01-17 주식회사 셀트리온 콩가수분해물의 저분자량 분획을 이용하여 시알산 함량이증가된 에리스로포이에틴을 생산하는 방법 및 그에 의하여생산된 시알산 함량이 증가된 에리스로포이에틴
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
SI1969007T1 (sl) * 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
DK2264060T3 (da) * 2006-01-26 2014-07-28 Recopharma Ab Sammensætninger og fremgangsmåder til inhibering af viral adhæsion
JP6084761B2 (ja) * 2006-04-05 2017-02-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
AU2007272957B2 (en) * 2006-07-13 2014-05-01 Wyeth Llc Production of glycoproteins
KR20090074040A (ko) 2006-09-13 2009-07-03 아보트 러보러터리즈 세포 배양의 개선
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US20080145893A1 (en) * 2006-09-17 2008-06-19 Excellegene Sa Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection
WO2008069244A1 (ja) * 2006-12-05 2008-06-12 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法
CA2682744C (en) * 2007-04-16 2015-10-06 Momenta Pharmaceuticals, Inc. Methods related to cell surface glyosylation
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
ES2657055T3 (es) * 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
EP4269578B8 (en) 2008-03-06 2024-07-17 Halozyme, Inc. Soluble hyaluronidase composition
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
CA2720610C (en) 2008-04-07 2016-08-23 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
MX2010011598A (es) 2008-04-22 2010-12-15 Univ Rockefeller Metodos para identificar compuestos anti-inflamatorios.
JP5524214B2 (ja) 2008-09-15 2014-06-18 ジェネンテック， インコーポレイテッド 細胞容積モル浸透圧濃度を調節するための組成物および方法
EP2350127B1 (en) * 2008-10-20 2015-01-28 AbbVie Inc. Isolation and purification of antibodies using protein a affinity chromatography
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
EP2367936B1 (en) 2008-12-09 2016-03-02 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
SG10201510640QA (en) 2009-10-26 2016-01-28 Hoffmann La Roche Method For The Production Of A Glycosylated Immunoglobulin
LT2501822T (lt) 2009-11-17 2017-10-25 E. R. Squibb & Sons, L.L.C. Padidintos baltymų produkcijos būdai
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
NO2538968T3 (cg-RX-API-DMAC7.html) * 2010-02-24 2018-03-31
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
RU2580020C2 (ru) 2011-04-29 2016-04-10 Биокон Рисерч Лимитед Способ снижения гетерогенности антител и способ получения соответствующих антител
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CN102839157A (zh) * 2012-07-12 2012-12-26 扬州大学 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
NO2760138T3 (cg-RX-API-DMAC7.html) 2012-10-01 2018-08-04
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ES2633960T3 (es) 2012-10-15 2017-09-26 Bristol-Myers Squibb Company Procesos de cultivo de células de mamífero para la producción de proteínas
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP3017303B1 (en) 2013-07-04 2018-01-03 F.Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
CN105431454A (zh) 2013-07-06 2016-03-23 卡迪拉保健有限公司 用于生产单克隆抗体的改进方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102280638B1 (ko) * 2014-02-27 2021-07-22 에프. 호프만-라 로슈 아게 재조합 당단백질 제조에서의 세포 성장 및 글리코실화의 조절
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2017516484A (ja) * 2014-06-03 2017-06-22 ルピン・リミテッド タンパク質生産のための細胞培養工程
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3377093B1 (en) 2015-11-19 2022-07-13 Takeda Pharmaceutical Company Limited Recombinant human c1 esterase inhibitor and uses thereof
RU2724536C2 (ru) * 2015-12-29 2020-06-23 Н.В. Нютрисиа Ферментированная молочная смесь с неперевариваемыми олигосахаридами
EP3717656B1 (en) * 2017-11-30 2024-03-13 F. Hoffmann-La Roche AG Process for culturing mammalian cells
CA3117447C (en) 2018-11-13 2024-06-04 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CA3159586A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
MX2023002417A (es) 2020-08-31 2023-03-22 Regeneron Pharma Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CN118076885A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH计校准与校正
KR20240167714A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 고역가 항체의 제조 방법
WO2025219232A1 (en) 2024-04-15 2025-10-23 Evonik Operations Gmbh Application of small peptides supplemented cell culture media for improved cell performance

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926723A (en) 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
JPS5938488B2 (ja) 1979-05-07 1984-09-17 株式会社東芝 空気調和機
EP0097353B1 (en) * 1982-06-21 1990-08-16 The Wellcome Foundation Limited Improved process for interferon production
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4724206A (en) * 1984-02-13 1988-02-09 Damon Biotech, Inc. Protein production using hypertonic media
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
JPH0639919B2 (ja) 1985-08-29 1994-05-25 トヨタ自動車株式会社 過給機付き内燃機関の異常判別装置
GB8606386D0 (en) * 1986-03-14 1986-04-23 Celltech Ltd Production of protein
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988001643A1 (en) 1986-08-29 1988-03-10 Endotronics, Inc. Method of culturing cells
JPH01257492A (ja) * 1987-03-05 1989-10-13 Green Cross Corp:The 異種蛋白質の生産増強方法
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
CA1312030C (en) * 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US5151359A (en) * 1988-05-19 1992-09-29 Mitsui Toatsu Chemicals Incorporated Method for producing of human tissue type plasminogen activator
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
KR0132666B1 (en) * 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5096816A (en) * 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) * 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
WO1993010260A1 (en) * 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
JP3523293B2 (ja) † 1993-07-19 2004-04-26 住友製薬株式会社 インターフェロンの産生増強法
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP5515221B2 (ja) † 2008-01-28 2014-06-11 日油株式会社 ポリオキシエチレンソルビタン脂肪酸エステルの製造方法

Also Published As

Publication number Publication date
HK1017903A1 (en) 1999-12-03
IL122398A0 (en) 1998-06-15
DE69637867D1 (de) 2009-04-23
SI0832189T2 (sl) 2008-12-31
CZ293719B6 (cs) 2004-07-14
SI0832189T1 (sl) 2006-02-28
TW516962B (en) 2003-01-11
PL185484B1 (pl) 2003-05-30
UA47428C2 (uk) 2002-07-15
SI1609853T1 (sl) 2009-08-31
BR9609150A (pt) 1999-02-23
EP0832189B1 (en) 2005-08-17
EP1609853B2 (en) 2020-01-22
ES2324046T3 (es) 2009-07-29
CZ390997A3 (cs) 1998-06-17
BG63213B1 (bg) 2001-06-29
AR011439A2 (es) 2000-08-16
DK0832189T4 (da) 2008-10-27
HU226420B1 (en) 2008-12-29
TR199701543T1 (xx) 1998-05-21
EP0832189B2 (en) 2008-07-09
NO975674D0 (no) 1997-12-05
GEP20012519B (en) 2001-08-27
CN1186514A (zh) 1998-07-01
RO120267B1 (ro) 2005-11-30
ZA964776B (en) 1997-12-08
CN1166772C (zh) 2004-09-15
EP1609853B1 (en) 2009-03-11
EP0832189A1 (en) 1998-04-01
DE69635076T2 (de) 2006-06-01
KR19990022473A (ko) 1999-03-25
AU717847B2 (en) 2000-04-06
NO975674L (no) 1998-02-06
SI1609853T2 (sl) 2020-07-31
IS2614B (is) 2010-04-15
SK167097A3 (en) 1998-07-08
US5705364A (en) 1998-01-06
MX9709452A (es) 1998-06-30
IL122398A (en) 2001-12-23
JP2007190024A (ja) 2007-08-02
CA2220684C (en) 2002-11-12
NZ310202A (en) 1999-10-28
BG102101A (en) 1998-07-31
TW426734B (en) 2001-03-21
JPH11507523A (ja) 1999-07-06
EP1609853A1 (en) 2005-12-28
PT1609853E (pt) 2009-06-09
JP4348376B2 (ja) 2009-10-21
WO1996039488A1 (en) 1996-12-12
KR100496356B1 (ko) 2005-11-25
ES2248812T3 (es) 2006-03-16
DK1609853T3 (da) 2009-06-02
DK0832189T3 (da) 2005-11-21
HUP9900920A2 (hu) 1999-07-28
ES2248812T5 (es) 2008-12-16
EA001215B1 (ru) 2000-12-25
HUP9900920A3 (en) 2001-06-28
SA96170351B1 (ar) 2006-07-04
OA10753A (en) 2002-12-11
DE69635076T3 (de) 2009-01-15
NO322276B1 (no) 2006-09-04
ATE302266T1 (de) 2005-09-15
MY113496A (en) 2002-03-30
SK282658B6 (sk) 2002-11-06
ATE425245T2 (de) 2009-03-15
DK1609853T4 (da) 2020-04-06
PL323737A1 (en) 1998-04-14
AU6095296A (en) 1996-12-24
ES2324046T5 (es) 2020-09-14
CA2220684A1 (en) 1996-12-12
DE69635076D1 (de) 2005-09-22
IS4626A (is) 1997-12-03
EA199700364A1 (ru) 1998-04-30
HK1087151A1 (en) 2006-10-06

Similar Documents

Publication Publication Date Title
AR004940A1 (es) Procedimiento para controlar la cantidad de acido sialico presente sobre una cadena lateral de oligosacaridos de una glicoproteina producida por cultivo en una celula hospedante de mamifero.
Scoma et al. Sustained H2 production in a Chlamydomonas reinhardtii D1 protein mutant
TW200512297A (en) Mammalian cell culture processes for protein production
EA201270469A1 (ru) Способы культивирования клеток млекопитающих для получения белка
DE60044310D1 (de) Verfahren zur Herstellung von Oligosacchariden
SI1428878T1 (sl) Postopek za proizvodnjo in čiščenje eritropoietina
CY1107771T1 (el) Μεθοδος για την παραγωγη χονδρινων εμφυτευματων απο in vitro καλλιεργημενα χονδροκυτταρα
AR061976A1 (es) Produccion de glicoproteinas
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
JP2011518790A5 (cg-RX-API-DMAC7.html)
CA2209211A1 (en) Production of a contractile smooth muscle
Renvoisé et al. Emerging themes of ER organization in the development and maintenance of axons
Roos et al. Biochemical studies on cell fusion. II. Control of fusion response by lipid alteration.
ES2556454T3 (es) Proceso para producción de proteínas
FR2389673A1 (cg-RX-API-DMAC7.html)
EP0245481A4 (en) YEAST STRAINS.
Borré et al. Production of lytic plaques of viral origin in Penicillium
GB1198071A (en) Improvements in or relating to Prostaglandin Analogues and the Manufacture thereof
Voccoli et al. Mitochondrial remodeling in differentiating neuroblasts
Kimelberg et al. Cell growth and ouabain-sensitive 86Rb+ uptake and (Na++ K+)-ATPase activity in 3T3 and SV40 transformed 3T3 fibroblasts
CN106635972B (zh) 成纤维细胞的培养基及其制备方法
Aziz et al. The origin of the nascent blastocoele in preimplantation mouse embryos ultrastructural cytochemistry and effect of chloroquine
CN102517347A (zh) 一种采用半连续发酵工艺制备葡萄糖酸钠的方法
ES2181899T3 (es) Procedimiento para la produccion de acido azetidin-2-carboxilico enantiomericamente puro.
KR20180018171A (ko) 강염기를 이용한 이산화탄소 고정을 통한 미세조류 배양방법

Legal Events

Date Code Title Description
FG Grant, registration